Macrogen Europe, a leading Sanger sequencing service provider and subsidiary of Macrogen Inc., is set to establish its presence at the Switzerland Innovation Park Basel Area on the Novartis Campus. With a focus on genome research activities, Macrogen Europe, headquartered in Amsterdam, aims to expand its footprint in Switzerland, leveraging its existing presence in Basel. The move is part of the company's strategy to enhance its in-house laboratory sequencing capabilities.
Initiated through collaboration with the Swiss Business Hub Korea and Basel Area Business & Innovation, Macrogen Europe's decision to choose Novartis Campus reflects its commitment to being at the forefront of the life sciences industry. Notably, the company was honored as the Top Sanger Sequencing Services Company 2023 by "Life Sciences Review," affirming its dedication to supporting genomics researchers in Europe and Africa since 2008.
Bongcho Kim, CEO of Macrogen Europe, emphasizes the company's commitment to minimizing research time, stating,
"Our powerful sequencing services are designed to take up as little research time as possible because project delays are simply not an option for us."
The initial phase involves establishing a presence in Basel with two employees and subsequently expanding the local workforce to between five and ten staff members at a dedicated laboratory in Switzerland. Basel's appeal lies in its existing life sciences cluster and central location on the border with Germany and France. The move marks a significant step in Macrogen Europe's strategic expansion within the European market.
You can read the full article in the official website of Innovation Park Basel Area